The UC Davis Medical Center HIV/AIDS research office located at CARES is headed by Dr. Richard B. Pollard. Dr. Pollard brings a wealth of knowledge with over 25 years experience in studying and treating HIV disease in over 10,000 patients. The research office is staffed with internationally known Infectious Disease physicians who specialize in treating HIV, physician assistants, research nurses, scientists, pharmacists and other clinical and research personnel. The UC Davis HIV/AIDS research office is committed to offering state-of-the-art patient care and research clinical trials to HIV/AIDS patients throughout Northern California.

Here is a list of currently available studies through the UC Davis Infectious Disease Resarch Unit at CARES:

ENROLLING:

Pfizer GALT – A Pilot Project of Immunologic, Pharmacologic and Virologic Correlates of GALT Immune Reconstitution Following Maraviroc Therapy

Major inclusion: No known GI pathology; naïve preferred, experienced on a case by case basis; CD4≥100 within 30 days of screening; CCR5 Tropism by Trofile ES; viral load ≤100,000; sensitive to NNRTI or NRTI

Major exclusion: Abnormal coagulation parameters; thrombocytopenia; contraindications to conscious sedation or endoscopy; anemia; No OI within 30 days of starting therapy

Argos AGS-004-003 – A Randomized, Double Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication during Analytical Treatment Interruption

Major inclusion: HIV-1+, male or female 18-60 years; HIV RNA <50 copies/mL at screening; CD4+ T cell > 450 and must have a sample in repository or Galt studies

Major exclusion: HIV immunotherapy including IL2; HIV-2 antibody; HTLV Type 1 or 2; Active Hep B or C or syphilis; concurrent autoimmune disease; history of lymph node irradiation

Pfizer 1067 (POEM) – An International, Mulitcenter, Prospective Observational Study of the Safety of Maraviroc Used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients

Major inclusion: appropriate HIV-1 tropism assay as a screening for eligibility to receive Maraviroc; 18 years or older; provide alternate contact person who can be contacted regarding patient’s whereabouts and survival status; provide social security number

Major exclusion: pregnancy or lactating; recipient of a small molecule CCR5 inhibitor other than Maraviroc

Viiv Healthcare-Pfizer 1098 – A Multicenter, Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety of Maraviroc in Combination with other Antiretroviral Agents in HIV-1 Infected subjects Co-infected with Hepatitis C and or Hepatitis B Virus

Major inclusion: previously failed HCV treatment, HCV and or HBV (+), never on Maravoric, must be on HIV treatment, willing to initiate and remain on randomized treatment without any changes or additions to the background treatment, except for toxicity mgn or upon virologic failure

Major exclusion: currently receiving Maraviroc; no treatment for HCV or HBV within 3 years of starting on study

Idenix-005 - A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Infection

AMC-064: Evaluation of Colonal Ig DNA in Plasma from Patients with Aggressive B-cell Lymphoma

Major inclusion: HIV+, male or female 18+ years; diagnosis of an untreated B-cell lymphoma, including diffuse large B cell/immunoblastic, Burkitt’s, or Hodgkin’s lymphoma; available diagnostic material from fresh frozen tissue or formalin-fixed paraffin embedded tissue or willing to undergo repeat biopsy.

Major exclusion: Patients without surplus diagnostic material and unwilling to undergo a repeat biopsy.

Immunology Functional Assays for Quality Assurance

Both HIV positive and negative volunteers may be included depending on the assay that is being developed.

The purpose of this study is to evaluate the immune response or virus related measurements to certain viruses. Your blood will be tested using Immunologic or virologic assay designed to measure your response to viruses that you may have been infected with in the past.

Role of Menopause in HIV-1 Infected Associated Pathogenesis

Major inclusion: 3 groups: HIV+ females between 30-60 years, have not had chemotherapy or radiotherapy, have intact ovaries and uterus and are not currently on hormonal contraceptives; HIV+ females between 30-60 years on HAART for >5 years, have not had chemotherapy or radiotherapy, have intact ovaries and uterus and are not currently on hormonal contraceptives; HIV-1 sero-negative female healthy controls between 30-60.

GUT Study - HIV positive men and women to study the effects of HIV infection and anti-HIV therapy on the restoration of CD4+ T cells in the immune system of the gastrointestinal (GI) tract and the blood.

Major inclusion: 18 - 60 years old, planning to start or already on anti-HIV treatment, willing to undergo blood draw and upper endoscopy procedures, must have a friend or family member transport them to and from visits

UCSF MALT/GALT Study – Very Abbreviated Guide to the MALT/GALT study: Effects of HIV on Mucosal Immunity in the Gut and Endometrium

Major inclusion: Females age 18-44, HIV + for at least 3 years, with regular menstrual cycles (21-35 days). Intact uterus and cervix, not pregnant or breastfeeding and in one of the phenotype categories: Natural Controllers, Good CD4 Responders to HAART, Poor CD4 Responders to HAART, Off Treatment Progressors

Major exclusion: Hx of inflammatory bowel disease, bleeding dyscrasias, current anticoagulant therapy. Autoimmune disease or use of immunomodulatory therapies. Abnormal Pap of a grade higher then ASCUS in last 12 months (ASCUS PAP is OK in last 6 months if most recent Pap is normal). Delivery, breastfeeding, use of hormonal contraceptives, sex hormones or IUD in the last 6 months. Miscarriage or abortion in the last 4 months.